Aerogen has licensed its OnQ nebulizer technology to a San Francisco, California company, Dance Pharmaceuticals for development of a new inhaled insulin solution product. Dance founder John S. Patton was a co-founder of Inhale Therapeutics, which later became Nektar and developed Exubera inhaled insulin. Read the companies’ press release.
Dance and Aerogen developing inhaled insuin product
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
